​
​

NeuroSense Therapeutics Ownership | Who Owns NeuroSense Therapeutics?

OverviewFinancialsChart

NeuroSense Therapeutics Ownership Summary

NeuroSense Therapeutics is owned by 10.85% institutional investors, 25.43% insiders, and 63.72% retail investors. Meitav investment house is the largest institutional shareholder, holding 0.26% of NRSN shares. Fidelity Nasdaq Composite Index is the top mutual fund, with 0.06% of its assets in NeuroSense Therapeutics shares.

NRSN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockNeuroSense Therapeutics10.85%25.43%63.72%
SectorHealthcare Stocks 47.25%8.01%44.75%
IndustryBiotech Stocks 45.35%7.81%46.83%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Nasdaq Composite Index11.96K0.06%-

NRSN Ownership FAQ

Who Owns NeuroSense Therapeutics?

NeuroSense Therapeutics shareholders are primarily institutional investors at 10.85%, followed by 25.43% insiders and 63.72% retail investors. The average institutional ownership in NeuroSense Therapeutics's industry, Biotech Stocks , is 45.35%, which NeuroSense Therapeutics falls below.

Who owns the most shares of NeuroSense Therapeutics?

NeuroSense Therapeutics’s largest shareholders are Meitav investment house (40K shares, 0.26%), Xtx topco (32.65K shares, 0.21%), and Geode capital management (11.96K shares, 0.08%). Together, they hold 0.55% of NeuroSense Therapeutics’s total shares outstanding.

Does Blackrock own NeuroSense Therapeutics?

BlackRock is not among the top 10 institutional shareholders of NeuroSense Therapeutics.

Who is NeuroSense Therapeutics’s biggest shareholder by percentage of total assets invested?

Xtx topco is NeuroSense Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.00% of its assets in 32.65K NeuroSense Therapeutics shares, valued at 36.57K$.

Who is the top mutual fund holder of NeuroSense Therapeutics shares?

Fidelity Nasdaq Composite Index is the top mutual fund holder of NeuroSense Therapeutics shares, with 0.06% of its total shares outstanding invested in 11.96K NeuroSense Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools